Format

Send to

Choose Destination
Drug Discov Today. 2015 Dec;20(12):1433-8. doi: 10.1016/j.drudis.2015.05.013. Epub 2015 Jul 3.

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.

Author information

1
Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
2
Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
3
Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
4
Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: fmeric@mdanderson.org.

Abstract

The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.

PMID:
26148707
PMCID:
PMC5648066
DOI:
10.1016/j.drudis.2015.05.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center